Transformation to Small Cell Lung Cancer as an Acquired Resistance Mechanism in EGFR-mutant Lung Adenocarcinoma: A Case Report of Complete Response to Etoposide and Cisplatin

2015 ◽  
Vol 101 (3) ◽  
pp. e96-e98 ◽  
Author(s):  
Ki-Eun Hwang ◽  
Jae-Wan Jung ◽  
Su-Jin Oh ◽  
Mi-Jeong Park ◽  
Young-Jun Shon ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Acquired Resistance ◽  
Resistance Mechanism ◽  
Complete Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutant

scholarly journals Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer

Pharmaceutics ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1478
Author(s):  
Frank Aboubakar Nana ◽  
Sebahat Ocak
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Acquired Resistance ◽  
Resistance Mechanism ◽  
Resistance Mechanisms ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutant ◽  
Braf V600 Mutation

Osimertinib has become a standard of care in the first-line treatment of advanced-stage non-small-cell lung cancer (NSCLC) harboring exon 19 and 21 activating mutations in the EGFR gene. Nevertheless, the 18.9-month median progression-free survival emphasizes the fact that resistance to osimertinib therapy is inevitable. Acquired resistance mechanisms to osimertinib in EGFR-driven NSCLC include MET amplification, EGFR C797S mutation, neuroendocrine differentiation, small-cell lung carcinoma histologic transformation, PD-L1 and KRAS amplifications and ESR1-AKAP12 and MKRN1-BRAF translocations, as well as BRAF V600 mutation. This last one represents 3% of the acquired resistance mechanisms to osimertinib. In this review, we discuss the rationale for EGFR/BRAF/MEK co-inhibition in the light of a clinical case of EGFR-mutant NSCLC developing a BRAF V600 mutation as an acquired resistance mechanism to osimertinib and responding to the association of osimertinib plus dabrafenib and trametinib. Additionally, we discuss the acquired resistance mechanisms to osimertinib plus dabrafenib and trametinib combination in that context.

Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report

2018 ◽  
Vol 25 (8) ◽  
pp. 2007-2009 ◽  
Author(s):  
Kevin Sullivan ◽  
Chung-Shien Lee
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Pemetrexed is an antifolate metabolite used to treat non-small cell lung cancer in the adjuvant and advanced setting. It is commonly known to cause rash, diarrhea, fatigue, mucositis, and myelosuppression. We report a case of a patient receiving adjuvant cisplatin and pemetrexed for non-small cell lung adenocarcinoma and experienced severe rhabdomyolysis.

Sign in / Sign up

Export Citation Format

Share Document